Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Lipoprotein-associated phospholipase A2: pathogenic mechanisms and clinical utility for predicting cardiovascular events.

Literature DB >> 16901407

Lipoprotein-associated phospholipase A2: pathogenic mechanisms and clinical utility for predicting cardiovascular events.

Abstract

Lipoprotein-associated phospholipase A(2 )(Lp-PLA(2)), a member of the phospholipase superfamily, circulates primarily bound to low-density lipoprotein and has been associated with cardiovascular disease risk in epidemiologic studies. However, it has not been established whether Lp-PLA(2) is a risk marker or a risk factor. Identification of individuals with elevated Lp-PLA(2) may improve risk assessment, and Lp-PLA(2) may also provide an additional target of therapy. Statin therapy has been shown to reduce Lp-PLA(2), and selective inhibitors of Lp-PLA(2) are under development. Additional research is needed to further determine the role of Lp-PLA(2) in atherogenesis and atherothrombotic events.

Entities: Disease Gene

Mesh：

Substances：

Year: 2006 PMID： 16901407 DOI： 10.1007/s11883-006-0034-8

Source DB: PubMed Journal: Curr Atheroscler Rep ISSN： 1523-3804 Impact factor: 5.113

68 in total

1. Association between Lp-PLA2 and coronary artery disease: focus on its relationship with lipoproteins and markers of inflammation and hemostasis.

Authors: Natalie Khuseyinova; Armin Imhof; Dietrich Rothenbacher; Gerlinde Trischler; Silke Kuelb; Hubert Scharnagl; Winfried Maerz; Hermann Brenner; Wolfgang Koenig
Journal: Atherosclerosis Date: 2005-04-14 Impact factor: 5.162

2. Lipoprotein-associated phospholipase A2 and measures of extracoronary atherosclerosis: the Rotterdam Study.

Authors: Isabella Kardys; Hok-Hay S Oei; Irene M van der Meer; Albert Hofman; Monique M B Breteler; Jacqueline C M Witteman
Journal: Arterioscler Thromb Vasc Biol Date: 2005-12-22 Impact factor: 8.311

3. N-linked glycosylation of macrophage-derived PAF-AH is a major determinant of enzyme association with plasma HDL.

Authors: A D Tselepis; S A Karabina; D Stengel; R Piédagnel; M J Chapman; E Ninio
Journal: J Lipid Res Date: 2001-10 Impact factor: 5.922

4. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme.

Authors: A D Tselepis; C Dentan; S A Karabina; M J Chapman; E Ninio
Journal: Arterioscler Thromb Vasc Biol Date: 1995-10 Impact factor: 8.311

5. Plasma PAF acetylhydrolase in non-insulin dependent diabetes mellitus and obesity: effect of hyperinsulinemia and lovastatin treatment.

Authors: G B Kudolo; P Bressler; R A DeFronzo
Journal: J Lipid Mediat Cell Signal Date: 1997-11

6. Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: the CARDIA study.

Authors: Carlos Iribarren; Myron D Gross; Jeanne A Darbinian; David R Jacobs; Stephen Sidney; Catherine M Loria
Journal: Arterioscler Thromb Vasc Biol Date: 2004-10-21 Impact factor: 8.311

Review 7. Phospholipase A2.

Authors: Makoto Murakami; Ichiro Kudo
Journal: J Biochem Date: 2002-03 Impact factor: 3.387

8. Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB.

Authors: Vasilis Tsimihodimos; Sonia-Athena P Karabina; Afroditi P Tambaki; Eleni Bairaktari; John A Goudevenos; M John Chapman; Moses Elisaf; Alexandros D Tselepis
Journal: Arterioscler Thromb Vasc Biol Date: 2002-02-01 Impact factor: 8.311

9. Lack of association between carotid intima-media thickness and PAF-acetylhydrolase mass and activity in patients with primary hyperlipidemia.

Authors: Dimitrios N Kiortsis; Sofia Tsouli; Evangelia S Lourida; Vasilios Xydis; Maria I Argyropoulou; Moses Elisaf; Alexandros D Tselepis
Journal: Angiology Date: 2005 Jul-Aug Impact factor: 3.619

Lipoprotein-associated phospholipase A2: pathogenic mechanisms and clinical utility for predicting cardiovascular events.

1. Association between Lp-PLA2 and coronary artery disease: focus on its relationship with lipoproteins and markers of inflammation and hemostasis.

2. Lipoprotein-associated phospholipase A2 and measures of extracoronary atherosclerosis: the Rotterdam Study.

3. N-linked glycosylation of macrophage-derived PAF-AH is a major determinant of enzyme association with plasma HDL.

4. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme.

5. Plasma PAF acetylhydrolase in non-insulin dependent diabetes mellitus and obesity: effect of hyperinsulinemia and lovastatin treatment.

6. Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: the CARDIA study.

Review 7. Phospholipase A2.

8. Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB.

9. Lack of association between carotid intima-media thickness and PAF-acetylhydrolase mass and activity in patients with primary hyperlipidemia.

10. Ischemia aggravating effects of platelet-activating factor in acute myocardial ischemia.

Review 1. Recent developments with lipoprotein-associated phospholipase A2 inhibitors.

Review 2. The role of lipoprotein-associated phospholipase A2 as a marker for atherosclerosis.

Review 3. Lipoprotein(a): a promising marker for residual cardiovascular risk assessment.

4. Role of secretory phospholipase A₂ in women with metabolic syndrome.